Given that several studies have shown that anthracycline-containing and anthracycline-free chemotherapy regimens lead to comparable outcomes in HER2-positive breast cancer, we consider it unlikely that this has substantially affected our results [6, 8, 17, 37]. Here, ERBB2 is linked to breast carcinoma.